Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) (clinicaltrials.gov) - Sep 25, 2026 - P2 | N=25 | Not yet recruiting | Sponsor: University of Utah | Trial completion date: Jun 2035 ➔ Nov 2035 | Initiation date: Jun 2026 ➔ Nov 2026 | Trial primary completion date: Jun 2034 ➔ Nov 2034
Trial completion date • Trial initiation date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin's Lymphoma • Waldenstrom Macroglobulinemia
|